Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.
The disposition and effect on hemostasis of a single 150 mg dose of sulindac was studied in young healthy subjects and in older patients with arthritis. Older patients were restudied after 2 weeks of sulindac, 150 mg b.i.d. The only difference in disposition of the first dose was a reduced plasma sulfone metabolite concentration in the elderly patients with arthritis. Chronic sulindac dosing resulted in accumulation of the drug and its sulfone and sulfide metabolites in plasma to a greater extent than previously reported for young subjects. No differences in renal clearance of sulindac and its sulfone metabolite related to age or chronic drug dosing were observed. No renal excretion of the active sulfide metabolite was detected. Bleeding time in the elderly patients was shorter than in the young healthy subjects before sulindac dosing, but was prolonged in the elderly patients after 2 weeks of dosing to values similar to control data from the young healthy subjects. This change correlated weakly with plasma sulfide metabolite concentrations. Differences in bleeding time were not reflected in changes in platelet aggregation induced by adenosine diphosphate either with respect to age or chronic drug dosing. Our data provide no justification for lowering the recommended dose of sulindac for patients older than 65 years of age.
D000328:Adult; D000368:Aged; D000375:Aging; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects; D005260:Female; D006801:Humans; D007192:Indenes / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects; D013467:Sulindac / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use / Q000652:urine
D007192:Indenes; D013467:Sulindac; C025462:sulindac sulfide; C025463:sulindac sulfone